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Chronic graft-versus-host disease (cGVHD) is a serious and frequent complication of allogeneic hemato-
poietic stem cell transplantation (HCT). Currently, no biomarkers for prediction and diagnosis of cGVHD are
available. We performed a large prospective study focusing on noninvasive biomarkers for National
Institutes of Healthedeﬁned cGVHD patients (n ¼ 163) in comparison to time-matched HCT recipients who
never experienced cGVHD (n ¼ 64), analyzed from day 100 after HCT. In logistic regression analysis,
CD19þCD21low B cells (P ¼ .002; hazard ratio [HR], 3.31; 95% conﬁdence interval [CI], 1.53 to 7.17) and
CD4þCD45RAþCD31þ T cells (P < .001; HR, 3.88; 95% CI, 1.88 to 7.99) assessed on day 100 after HCT were
signiﬁcantly associated with subsequent development of cGVHD, independent of clinical parameters. A
signiﬁcant association with diagnosis of cGVHD was only observed for CD19þCD21low B cells (P ¼ .008; HR,
3.00; 95% CI, 1.33 to 6.75) and CD4þCD45RAþCD31þ T cells (P ¼ .017; HR, 2.80; 95% CI, 1.19 to 6.55).
CD19þCD21low B cells were found to have the highest discriminatory value with an area under the receiver
operating curve of .77 (95% CI, .64 to .90). Our results demonstrate that CD19þCD21low B cells and
CD4þCD45RAþCD31þ T cells are signiﬁcantly elevated in patients with newly diagnosed cGVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (cGVHD) is the leading
cause of nonrelapse morbidity and mortality in survivors of
allogeneic hematopoietic cell transplantation (HCT) [1-3].
Affected patients present unique diagnostic clinical features
[4], and most frequently skin, oral mucosa, and eyes are
involved [3,4]. The precise immunologicmechanisms leading
to cGVHD currently still remain unclear [5,6]. Chronic GVHD
is characterized by a combination of allogeneic and
autoimmune dysregulation with profound immune deﬁ-
ciency. Donor T cells responding to allogeneic antigens in the
patient are of critical importance for the development ofedgments on page 257.
quests: Prof. Hildegard T. Greinix, Med-
fuer Innere Medizin I, Knochenmark-
el 18-20, A-1090 Vienna, Austria.
ix@meduniwien.ac.at (H.T. Greinix).
14.11.010
ty for Blood and Marrow Transplantation.cGVHD, as T cell depletion from the donor graft is known to
prevent cGVHD. The antigens recognized by donor-derived
host-reactive T cell subpopulations are not well character-
ized, and the response of donor T cells against patient
alloantigens appears to be highly heterogeneous, suggesting
a contribution of noneTcell populations to cGVHD [6]. Donor
B cell responses to recipient H-Y antigens have been signiﬁ-
cantly associated with the development of cGVHD after
gender-mismatched HCT [7]. Recent data reveal an impor-
tant role for B cells in the pathogenesis of cGVHD [8-12].
Patients with cGVHD have altered B cell homeostasis
[8-10,13], delayed B cell reconstitution, and elevated plasma
B celleactivating factor (BAFF) levels, resulting in signiﬁ-
cantly increased BAFF/B cell ratios [9,10,13]. BAFF is a
cytokine of the tumor necrosis family that plays an important
role in B cell homeostasis [14], and when BAFF is in excess,
peripheral tolerance may be lost and autoreactive B cells
potentially survive [15]. We previously published a report
that indicated that relative numbers of CD19þCD21low B cells
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compared with healthy controls and that an increase of
CD19þCD21low B cells above 15% was signiﬁcantly associated
with occurrence of severe infections (P¼ .003), a ﬁnding that
was most pronounced in patients with long-lasting
active cGVHD [8]. Furthermore, patients with hypogamma-
globulinemia had signiﬁcantly higher proportions of
CD19þCD21low B cells compared with cGVHD patients with
hypergammaglobulinemia or normogammaglobulinemia
[9]. Patients with newly diagnosed National Institutes of
Health (NIH)edeﬁned bronchiolitis obliterans syndrome, as
sign of lung involvement of cGVHD, had signiﬁcantly higher
percentages of CD19þCD21low B cells comparedwith patients
without cGVHD [16]. A cut-off point above 9% was optimal
for diagnosing bronchiolitis obliterans syndrome in patients
with ﬁrst drop of pulmonary function tests with a sensitivity
of 96% and a negative predictive value of 94%. In a small
study, proportions of CD19þCD21low B cells were signiﬁ-
cantly lower in patients achieving a complete resolution of
cGVHD with extracorporeal photopheresis treatment
comparedwith extracorporeal photopheresis nonresponders
[17]. Thus, CD19þCD21low B cells could serve as potential
biomarkers for activity of cGVHD.
Thymic epithelial damage caused by conditioning
regimens and/or acute GVHD supposedly leads to dysre-
gulation of central tolerance mechanisms during the
reconstitution of the immune system after HCT [18].
Defective negative selection of T cells in the thymus can lead
to a disease state resembling autoimmune disorders, similar
to those observed in cGVHD patients. CD31 (PECAM-1) is a
130-kDa transmembrane glycoprotein expressed by endo-
thelial cells, platelets, monocytes, neutrophils, and certain T
cell subpopulations. Under physiological conditions and in
the reconstitution phase after HCT, CD31 is known to be an
excellent ﬂow cytometric marker of recent thymic emi-
grants in CD4þCD45RAþ naïve T cells containing high
numbers of T cell receptor (TCR) rearrangement excision
circle (TREC)-bearing cells [19,20]. Such T cells are respon-
sible for long-term T cell reconstitution and are thought to
result from the recapitulation of T cell ontogeny from
donor-derived progenitors in the recipient thymus [21].
CD31 is downregulated on the majority of CD4þ T cells upon
their transition to the memory phenotype [22].
CD4þCD45RAþCD31 T cells are characterized by a drasti-
cally reduced TREC content and a restricted oligoclonal TCR
repertoire, as CD31 reportedly is downregulated during
homeostatic expansion of naïve T cells after ligation of the
TCR with speciﬁc MHC/self-peptide ligands within sec-
ondary lymphoid organs [23,24].
CD4þCD25þFOXP3þ regulatory T (Treg) cells are a func-
tionally distinct subset of mature T cells selected in the
thymus and are known to play a central role in the mainte-
nance of self-tolerance and immune homeostasis [25].
Conﬂicting data have been reported concerning the role of
Treg cells in the development of cGVHD [26,27]. Matsuoka
et al. reported altered Treg cell homeostasis in patients with
lymphopenia, assuming that impaired thymic Treg cell gen-
eration and increased sensitivity to apoptosis contribute to
low Treg cell numbers in patients with cGVHD [28]. Of note,
low-dose interleukin-2 administration resulted in enhance-
ment of Treg thymic neogenesis, restoration of Treg
homeostasis, and clinical improvement of cGVHD [29].
The NIH consensus recommended research in cGVHD
biomarkers [30], as so far only limited data from small and
often single-center studies are available [8-10,16,31].Frequently, patients with long-lasting cGVHD have been re-
ported, whereas data on newly diagnosed NIH-deﬁned
cGVHD patients are lacking. Therefore, we performed a
large prospective study to enumerate immune cell sub-
populations previously reported in patients with long-lasting
cGVHD in the peripheral blood (PB) at predeﬁned time points
after HCT to identify associations between early post-
transplantation cellular and plasma variables and later
occurrence of cGVHD. Our second objective was to identify
associations between cellular and plasma variables and
newly diagnosed cGVHD. Our aim was to prospectively
assess recently established B cell subpopulations [8,9] as
noninvasive biomarkers for prediction and diagnosis of
cGVHD, analyzing NIH-deﬁned cGVHD patients compared
with allogeneic HCT recipients never experiencing cGVHD.
PATIENTS AND METHODS
Patients and Trial Conduct
Between 2005 and 2013, all consecutive patients given an allogeneic
HCT at the Medical University of Vienna, Austria (n ¼ 211) and all patients
from the University Hospital of Regensburg, Germany (n ¼ 16) with
biomarker samples available, alive on day 100 after HCTwithout active acute
GVHD and malignant disease were asked to participate in this prospective
study. All patients gave written informed consent in accordance with the
Declaration of Helsinki. The study had the approval of the institutional
review boards.
Starting on day 100, 227 patients (Table 1) were evaluated every 3
months during routine follow-up visits in the outpatient clinic for presence
of GVHD and PB samples were obtained for ﬂow cytometry.
Transplantation Procedures
All patients underwent HCT on standard of care or institutional review
boardeapproved protocols and received antimicrobial and antifungal
prophylaxis according to institutional guidelines [32]. Acute GVHD was
graded using the modiﬁed Glucksberg criteria [33] and cGVHD according to
the NIH consensus criteria [4]. Cyclosporine A given for GVHD prophylaxis
was tapered starting on day 80 and discontinued in the never cGVHD cohort
around days 160 to 180 after HCT. First-line treatment of both acute as well
as cGVHD consisted of corticosteroids.
Isolation of Blood Cells, Immunophenotyping, and Flow Cytometry
Immunophenotyping of fresh whole blood cells was performed as
previously reported [8]. We used optimal concentrations of the directly
conjugated monoclonal antibodies (mAbs) CD3-APC (S4.1), CD4-FITC (VIT4),
CD8-PE (VIT 8), CD14-PE (MEM-18), CD16-PE (3G8), CD19-FITC (SJ25-C1),
CD21-PE (BU32), CD27-FITC (VIT14), CD31-FITC (WM59), CD56-PE
(MEM-188), CD45-FITC (VIT200), HLA-DR-PerCp-Cy5.5 (L243), CD11c-APC
(B-ly6), CD123-PE (9F5), and appropriate isotype controls for characteriza-
tion of B, T, dendritic cell, and natural killer (NK) cell subpopulations
(Supplementary Table 1). Data acquisition was performed on a FACS Calibur
ﬂow cytometer (Becton Dickinson, San Jose, CA) and FACS Canto II (Becton
Dickinson). Technicians determining the cell counts were blinded to the
clinical outcomes.
Assessment of BAFF by Enzyme-Linked Immunosorbent Assay
Patients’ plasma samples were examined for soluble BAFF by ELISA assay
(R&DSystems,Minneapolis,MN)according to themanufacturer’s instructions.
Statistical Analysis
Results of each clinical (patient and donor age, conditioning, stem cell
source, GVHD prophylaxis, prior acute GVHD, and Karnofsky performance
score) and lab (Supplementary Table 1) parameter were compared between
patients with cGVHD and those never experiencing cGVHD using the
Wilcoxon rank-sum test. An association was considered potentially signiﬁ-
cant in univariate analysis if the Wilcoxon rank-sum test P value was <.05
(2-tailed). For associations considered potentially signiﬁcant in univariate
analysis, multivariate analyses were performed using logistic regression.
Because various correlations between lab parameters were signiﬁcant in
univariate analysis, a factor analysis was performed after logarithmic
transformation and standardization [34,35]. The basic model predicting and
diagnosing cGVHD contained all lab biomarkers and, in case of correlation,
their composite variables instead. The resulting composite variables, as well
as other lab and clinical parameters signiﬁcant in univariate analysis, were
further used in logistic regression analysis.
Cut-off values were determined for each lab parameter-outcome
combination using receiver operating characteristic (ROC) curves (values
Table 1
Patient and Transplantation Characteristics
Characteristic All cGVHD Never cGVHD
No. of patients 227 163 (72) 64 (28)
Patient age, median
(range), yr
42 (17-73) 41 (17-73) 46 (20-65)
Patient gender
Male 115 (51) 82 (50) 33 (52)
Female 112 (49) 81 (50) 31 (48)
Donor age, median
(range), yr
36 (14-75) 36 (14-75) 36 (14-58)
Donor gender
Male* 133 (58) 94 (58) 39 (60)
Female 86 (39) 63 (42) 23 (37)
Diagnosis
AL 155 (68) 112 (69) 43 (66)
CML 16 (7) 14 (9) 2 (3)
Lymphoma 29 (13) 21 (13) 8 (12)
MDS 16 (7) 10 (6) 6 (9)
Othery 11 (5) 6 (4) 5 (8)
Disease status at HCT
Standard riskz 97 (43) 69 (42) 28 (44)
High riskz 130 (57) 94 (58) 36 (56)
Conditioning regimensx
Myeloablative 138 (60) 116 (71) 22 (34)
RIC 89 (39) 47 (29) 42 (66)
Stem cell donors
Related 67 (30) 48 (29) 19 (30)
Unrelated 160 (70) 115 (71) 45 (70)
HLA identical 196 (86) 138 (84) 58 (91)
HLA mismatched 31 (14) 25 (16) 6 (9)
Stem cell source
BM 15 (7) 11 (6.8) 4 (6)
PBSC 206 (91) 150 (92) 56 (88)
Cord blood 6 (2) 2 (1) 4 (6)
Median CD34þ
cells, median
(range),  106/kg
6.3 6.3 6.3
.6-11.5 .6-11.5 1.4-9.9
Prophylaxis of acute GVHD
CSA 9 (4) 5 (3) 4 (6)
CSA-MTXx 143 (63) 123 (70) 20 (31)
CSA-MMF 75 (33) 35 (21) 40 (63)
Follow-up, median
(range), mo
60 (4-123) 64 (4-120) 52 (4-123)
No. of patients (%) analyzed at time point
Day 100 185 (81) 137 (84) 48 (75)
Month 6 192 (85) 145 (89) 47 (73)
Month 9 155 (68) 123 (75) 32 (50)
Month 12 170 (75) 139 (85) 31 (48)
AL indicates acute leukemia; CML, chronic myeloid leukemia; MDS, mye-
lodysplastic syndrome; RIC, reduced-intensity conditioning; BM, bone
marrow; PBSC, peripheral blood stem cells; CSA, cyclosporine; MTX,
methotrexate; MMF, mycophenolate mofetil.
* Donor gender is missing in 8 patients’ information.
y Other diagnoses include chronic lymphocytic leukemia, severe aplastic
anemia, osteomyeloﬁbrosis, and myeloma.
z Standard risk was deﬁned as acute leukemia in ﬁrst or second complete
remission or chronic myeloid leukemia in ﬁrst chronic phase. High-risk
disease included myelodysplastic syndrome and advanced stage of acute
and chronic leukemia.
x P < .01; the association between groups is considered to be statistically
signiﬁcant.
Table 2
Characteristics of cGVHD
Characteristic No. of Patients %
Organ manifestations of cGVHD
Skin 120 77
Eyes 103 63
Oral mucosa 74 45
Liver 106 65
Lungs 58 36
GI 7 4
Genital 15 9
Joints 15 9
NIH severity score, at onset
Mild 92 56
Moderate 50 31
Severe 21 13
NIH severity score, at maximum
Mild 26 16
Moderate 53 32
Severe 84 52
Onset type of cGVHD
De novo 48 29
Quiescent 88 55
Progressive 27 17
Platelets below 100 g/L 46 28
Overlap cGVHD 36 22
Classic cGVHD 127 78
Karnofsky <80% at onset of cGVHD 23 14
Median time ﬁrst onset cGVHD in months
(range)
5.7 (2-29)
GI indicates gastrointestinal tract.
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and 90th interquartile range). The univariate analyses were performed using
SPSS version 20 (IBM Company, Chicago, IL).
Cumulative incidences of acute and cGVHD were estimated considering
relapse/progression and death as competing risk event [36]. Nonrelapse mor-
tality (NRM) was deﬁned as any death in the absence of the underlying malig-
nancy. Cumulative incidence of NRM was estimated using the Kaplan-Meier
method with adjustment for relapse as a competing risk event [36]. Overall
survival (OS) was calculated from the day of HCT to the day of death from any
cause or last follow-up. Patients were censored at the date of last contact.
RESULTS
We prospectively analyzed 227 patients including those
with cGVHD (n ¼ 163) and those never experiencing cGVHD(n ¼ 64) (Table 1). Median follow-up of surviving patients
was 60 (range, 4 to 123) months. The analyses included
clinical, cellular, and plasma variables as potential
biomarkers for prediction and diagnosis of cGVHD and its
outcome.Increased Percentages of CD19þCD21low B Cells and
CD4þCD45RAþCD31þ T Cells on Day 100 after HCT are
Signiﬁcantly Associated with Later Development of
cGVHD
Onset of cGVHD was observed at a median of 5.7 months
after HCT (Table 2). The cumulative incidence of overall
cGVHD, including NIH-deﬁned mild presentation, at 3 years
was 72% (95% conﬁdence interval [CI], 66% to 78%).
Table 3 summarizes all biomarkers assessed on day 100
after HCT that were signiﬁcantly different between patients
never experiencing cGVHD and those later presenting with
cGVHD. Compared with never cGVHD controls, patients with
later cGVHD had signiﬁcantly higher CD19þCD21low B cells
(23.5% versus 15.2%, P ¼ .004, Figure 1), CD4þ T cells (394
versus 127  106/L, P < .001), CD4þCD45RAþ naïve T cells
(28.7% versus 16.3%, P < .001), and CD4þCD45RAþCD31þ T
cells (13.5% versus 3.7%, P < .001).
Because some cellular subsets (CD3þ, CD4þ,
CD8þ; CD19þCD21low, CD19þIgDþCD27þ, CD4þCD45RAþ,
CD4þCD45RAþCD31þ) correlated with each other, a principal
component analysis was performed, revealing 3 composite
variables for logistic regression analysis (Supplementary
Table 2a). Only the composite variable CD19þCD21low/
CD19þIgDþCD27þB cells (P¼ .003; hazard ratio [HR], 4.34; 95%
CI, 1.62 to 11.61) as well as the composite variable
CD4þCD45RAþ/CD4þCD45RAþCD31þ T cells (P ¼ .001; HR,
5.48; 95% CI,1.95 to 15.33) assessed on day 100 after HCTwere
signiﬁcantly associated with later development of cGVHD,
independent of clinical parameters. This model achieved a
considerable pseudo-R2 (Nagelkerke R2 ¼ .577) [37].
Table 3
Signiﬁcant Differences in Cellular and Plasma Biomarkers on Day 100 after
HCT: Results of Univariate Analysis*
Variable Never cGVHD cGVHD P Value
CD19þCD21low B cells, % 15.2 23.5 .004
CD19þIgDþCD27þ memory
B cells, %
3.7 6.6 .007
CD3þ T cells  106/L 557 1199 <.001
CD4þ T cells  106/L 127 394 <.001
CD4þCD45RAþT cells, % 16.3 28.7 <.001
CD4þCD45RAþCD31þ T cells, % 3.7 13.5 <.001
CD8þ T cells  106/L 370 725 .015
CD3þCD56þ NKT cells  106/L 115 336 <.001
* Peripheral blood samples for analysis were obtained in all patients on
day 100 after HCT and patient cohorts were deﬁned according to never
experiencing cGVHD or developing cGVHDwithin the study follow-up time.
Patients with cGVHD diagnosed before day 100 after HCT (n ¼ 20) were
excluded from the analysis. Only parameters signiﬁcantly different between
these 2 patient cohorts are shown.
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were selected for logistic regression, a similar signiﬁcant
association with later development of cGVHD was observed
for CD19þCD21low B cells (P ¼ .002; HR, 3.31; 95% CI, 1.53 to
7.17) and CD4þCD45RAþCD31þ T cells (P < .001; HR, 3.88;
95% CI, 1.88 to 7.99) (Nagelkerke R2 ¼ .459) [37].
The cumulative incidence of clinically signiﬁcant cGVHD,
deﬁned as disease in need of systemic immunosuppression
and thus, NIH-deﬁned moderate and severe cGVHD, at 3
years was 23% (95% CI, 18% to 29%) and 37% (95% CI, 31% to
43%), respectively. Lab parameters signiﬁcantly associated
with later development of moderate and severe cGVHD in
univariate analysis (Supplementary Table 3) were the same
as previously observed for overall cGVHD. In logistic
regression analysis, CD19þCD21low B cells (P¼ .002; HR, 3.60;
95% CI, 1.59 to 8.15) and CD4þCD45RAþCD31þ T cells (P <
.001; HR, 4.19; 95% CI, 1.95 to 9.02) were signiﬁcantly asso-
ciated with later development of clinically signiﬁcant cGVHD
(Nagelkerke R2 ¼ .483) [37].Cellular Subpopulations Signiﬁcantly Associated with
Later Development of De Novo Onset and Quiescent/
Progressive Onset Type cGVHD
Onset of cGVHD can be distinguished between de novo
onset, deﬁned as occurrence of cGVHD without prior acute
GVHD, quiescent onset, deﬁned as absence of all symptomsFigure 1. Increased percentages of CD19þCD21low B cells (Left), absolute numbers of
analyzed on day 100 after hematopoietic cell transplantation are signiﬁcantly asso
Results in patients never experiencing cGVHD (No cGVHD cohort) are compared with t
are shown in box plots.C represents outliers. , represents mean, line in the box rof acute GVHD at onset of cGVHD, and progressive onset,
deﬁned as development of cGVHD during acute GVHD or its
treatment [3]. Because acute GVHD is a known risk factor for
the development of cGVHD [38] and residual changes due to
previous acute GVHD could have an impact on biomarker
levels, we compared assessments on day 100 of patients
with later onset of de novo cGVHD (no previous acute
GVHD, n ¼ 48) to patients never experiencing cGVHD (n ¼
64, Table 4). Besides CD19þIgDþCD27þ, noneclass-switched
memory B cells, and CD8þ T cells, no differences in predic-
tive biomarkers in comparison to analyses on cGVHD pa-
tients with quiescent/progressive onset type of disease
were observed. In logistic regression analysis, only the
composite variable CD4þCD45RAþ/CD4þCD45RAþCD31þ T
cells (P ¼ .039; HR, 5.56; 95% CI, 1.08 to 28.40) assessed on
day 100 after HCT was signiﬁcantly associated with de novo
onset cGVHD (Nagelkerke R2 ¼ .672), independent of clin-
ical parameters. When individual parameters of these
composite variables were selected for logistic regression, a
signiﬁcant association with later development of de novo
onset cGVHD was observed only for CD4þCD45RAþCD31þ T
cells (P ¼ .001; HR, 3.14; 95% CI, 1.56 to 6.32) (Nagelkerke
R2 ¼ .312).
In logistic regression analysis, only the composite
variables CD19þCD21low/CD19þIgDþCD27þ B cells (P ¼ .018;
HR, 8.68; 95% CI, 1.45 to 52.06) and CD4þCD45RAþ/
CD4þCD45RAþCD31þ T cells (P ¼ .034; HR, 7.22; 95% CI, 1.15
to 45.14) assessed on day 100 after HCT were signiﬁcantly
associated with later development of quiescent or
progressive onset cGVHD (Nagelkerke R2 ¼ .752), indepen-
dent of clinical parameters. Furthermore, CD19þCD21low B
cells (P ¼ .008; HR, 3.29; 95% CI, 1.35 to 8.01) and
CD4þCD45RAþ T cells (P ¼ .001; HR, 4.89; 95% CI, 1.93 to
12.36) were signiﬁcantly predictive for later quiescent or
progressive onset cGVHD (Nagelkerke R2 ¼ .507).
Increased Percentages of CD19þCD21low B Cells and
CD4þCD45RAþCD31þ T Cells are Signiﬁcantly Associated
with First Diagnosis of cGVHD
At ﬁrst onset of clinically signiﬁcant cGVHD, CD19þ B cells
(115 versus 261 106/L, P < .001, Figure 2) were signiﬁcantly
lower in patients with cGVHD compared with the never
cGVHD control (Table 5). CD19þCD21low B cells (18.3% versus
9.9%, P < .001), class-switched CD19þIgDCD27þ memory B
cells (6.6% versus 4.4%, P ¼ .014), CD4þCD45RAþ naïve T cellsCD4þ T cells (Center), and percentages of CD4þCD45RAþ naïve T cells (Right)
ciated with later development of chronic graft-versus-host disease (cGVHD).
hose in patients experiencing cGVHD at later time points (cGVHD cohort). Data
epresents the median.
Table 4
Signiﬁcant Differences in Cellular and Plasma Biomarkers on Day 100 after HCT: Results of Univariate Analysis*
Variable Never cGVHD De Novo cGVHD Quiescent/Progressive
cGVHD
P Value (Never
versus De Novo)
P Value (Never versus
Quiescent/Progressive)
CD19þCD21low B cells, % 15.2 20.8 25.1 .043 .005
CD19þIgDþCD27þ memory B cells, % 3.7 5.5 7.3 .125 .004
CD3þ T cells  106/L 557 1356 1144 .001 <.001
CD4þ T cells  106/L 126 533 346 <.001 <.001
CD4þCD45RAþ T cells, % 16.3 28.0 28.9 .002 <.001
CD4þCD45RAþCD31þ T cells, % 3.7 9.7 15.1 .002 <.001
CD8þ T cells  106/L 370 705 731 .056 .024
CD3þCD56þ NKT cells  106/L 115 516 255 .001 .004
Differences among patients who never experienced cGVHD and those who developed de novo cGVHD or quiescent/progressive onset type cGVHD at later time
points.
Signiﬁcant parameters are marked in bold.
* Peripheral blood samples for analysis were obtained in all patients on day 100 after HCT and patient cohorts were deﬁned according to never experiencing
cGVHD or developing de novo, quiescent or progressive onset type of cGVHD within the study follow-up time. Patients with cGVHD diagnosed before day 100
after HCT (n ¼ 20) were excluded from the analysis. Only parameters signiﬁcantly different between patient cohorts are shown marked in black.
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(15.9% versus 6.8%, P ¼ .003), and BAFF levels (6.3 ng/mL
versus 3.2 ng/mL, P ¼ .004) were signiﬁcantly higher in
patients with NIH-deﬁned moderate/severe cGVHD. Similar
ﬁndings were observed comparing patients with overall
cGVHD including NIH-deﬁned mild presentation to those
never experiencing cGVHD and comparing de novo onset
with quiescent/progressive (Table 6).
Fifty patients were on corticosteroid medication at
diagnosis of cGVHD and no signiﬁcant differences in cellular
subpopulations were observed between them and patients
without corticosteroid medication. However, patients on
corticosteroid doses above 30 mg/day (n ¼ 15) had signiﬁ-
cantly lower BAFF levels compared with those on lower
corticosteroid doses (2.2 versus 9.1 ng/mL, P < .001) or no
corticosteroid therapy at all (2.2 versus 5.7 ng/mL, P ¼ .011),
as previously reported [39].
Results of logistic regression analysis with the 4 composite
variables obtained from principal component analysis
(Supplementary Table 2B) are shown in Table 7. CD3CD56þ/
CD3CD56high NK cells, CD4þCD45RAþ/CD4þCD45RAþCD31þ
T cells, and BAFF/CD19þ/CD19þCD21low B cells were
signiﬁcantly associated with ﬁrst diagnosis of cGVHD,
independentof clinicalparameters (NagelkerkeR2¼ .441) [37].
When individual parameters of these composite variables
were selected for logistic regression, a signiﬁcant association
with ﬁrst diagnosis of cGVHD was only observed for
CD19þCD21low B cells (P¼ .008; HR, 3.00; 95% CI,1.33 to 6.75)Figure 2. Absolute numbers of CD19þ B cells (Left), percentages of CD19þCD21low B ce
distinguish patients with ﬁrst diagnosis of chronic graft-versus-host disease (cGVHD
cGVHD cohort). Data are shown in box plots.C represents outliers.and CD4þCD45RAþCD31þ T cells (P ¼ .017; HR, 2.80; 95% CI,
1.19 to 6.55) (Nagelkerke R2 ¼ .416). Similar signiﬁcant
results were obtained for ﬁrst diagnosis of NIH-deﬁned
moderate/severe cGVHD in logistic regression analyses
(Supplementary Table 4).
Only the composite variables BAFF/CD19þ/CD19þCD21low
B cells (P¼ .001; HR, 6.86; 95% CI, 2.14 to 21.98), CD3CD56þ/
CD3CD56high NK cells (P ¼ .036, HR, .38; 95% CI, .15 to .94),
and CD4þCD45RAþ/CD4þCD45RAþCD31þ T cells (P ¼ .015;
HR, 3.34; 95% CI, 1.25 to 8.90) were signiﬁcant for ﬁrst
diagnosis of quiescent and progressive onset type of cGVHD
in logistic regression analyses (Nagelkerke R2 ¼ .617) [37]. Of
note, CD19þCD21low B cells (P¼ .001; HR, 9.50; 95% CI, 2.47 to
36.49) as individual parameters were also signiﬁcant
(Nagelkerke R2 ¼ .595).
ROC analysis for these biomarkers distinguished clinically
signiﬁcant cGVHD from never cGVHDwith an area under the
curve of .80 (95% CI, .69 to .91) for the composite variable
BAFF/CD19þ/CD19þCD21low B cells (Figure 3), .77 (95% CI, .64
to .90), and .72 (95% CI, .60 to .85) for CD19þCD21low B cells
and BAFF alone, respectively (Supplementary Table 5). The
area under the curve for the composite variable
CD4þCD45RAþ/CD4þCD45RAþCD31þ T cells was .66 (95% CI,
.45 to .82). Of all variables, only CD19þCD21low B cell
percentages above the median (10.02%) were signiﬁcantly
associated with the presence of newly diagnosed cGVHD
(82% versus 18%, P ¼ .015), independent of clinical
parameters.lls (Center), and percentages of CD4þCD45RAþ naive T cells (Right) signiﬁcantly
cohort) from those never experiencing chronic graft-versus-host disease (No
Table 5
Signiﬁcant Differences in Cellular and Plasma Biomarkers in Patients at First Diagnosis of cGVHD Compared with Patients Never Experiencing cGVHD: Results of
Univariate Analysis*
Variable Never
cGVHD
cGVHD
Overall
cGVHD Mod/
Sev
P Value (Never versus
Overall cGVHD)
P Value (Never versus
Mod/Sev cGVHD)
CD19þ B cells  106/L 261 193 115 .033 <.001
CD19þCD21low B cells, % 9.9 15.9 18.3 .015 <.001
CD19þIgDCD27þ memory B cells, % 4.4 5.8 6.6 .323 .014
BAFF, ng/mL 3.2 5.6 6.3 .007 .004
CD4þ T cells  106/L 241 417 396 .001 .005
CD4þCD45RAþ T cells, % 14.5 28.9 31.1 <.001 <.001
CD4þCD45RAþCD31þ T cells, % 6.8 14.0 15.9 <.001 .003
CD3CD56þ NK cells  106/L 233 193 166 .021 .010
CD14þCD16þ monocytes  106/L 11.3 31.1 40.4 .059 .023
Mod indicates moderate; sev, severe.
Signiﬁcant parameters are marked in bold.
* In patients with cGVHD, peripheral blood samples were obtained at ﬁrst diagnosis of cGVHD before initiating immunosuppressive medication and results
were compared with samples obtained from patients never experiencing cGVHD at the same predeﬁned time points after HCT.
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Forty-eight patients (21%), including 29 with cGVHD
and 19 never experiencing cGVHD, died because of relapse
(n ¼ 29) or other causes, including of cGVHD (n ¼ 13),
infections (n ¼ 3), and organ toxicity (n ¼ 3).
The 5-year cumulative NRM for all patients was 10% (95%
CI, 6% to 14%). NRM was 11% (95% CI, 6% to 17%) and 8% (95%
CI, 0% to 16%) in patients never experiencing cGVHD and in
those with cGVHD, respectively. In univariate competing risk
regression analysis, higher patient age (P ¼ .021; HR, 1.04;
95% CI, 1.01 to 1.08), platelet counts <100 g/L (P < .001; HR,
14.00; 95% CI, 4.04 to 48.20), and Karnofsky performance
score < 80% at onset of cGVHD (P ¼ .033; HR, 3.18; 95% CI, 1.1
to 9.22) were signiﬁcantly associated with increased risk of
NRM. In addition, the composite variable CD4þCD45RAþ/
CD4þCD45RAþCD31þ T cells (P ¼ .021; HR, 2.61; 95% CI, 1.15
to 5.89) assessed on day 100 and the composite variables
CD4þCD45RAþ/CD4þCD45RAþCD31þ T cells (P ¼ .042; HR,
1.76; 95% CI, 1.02 to 3.05), as well as CD19þIgDCD27þ
memory B cells (P ¼ .032, HR, .66; 95% CI, .45 to .95) assessed
at diagnosis of cGVHD had a signiﬁcant impact on NRM.
The 5-year probability of OS was 79% for all patients and
82% and 71% for patients with cGVHD and those never
experiencing cGVHD (P ¼ .024). In univariate analysis,
advanced disease stage at HCT (75% versus 85%, P ¼ .04) and
patient age > 40 years (74% versus 86%, P ¼ .02) were
signiﬁcantly associated with worse OS. In the cGVHD cohort,
severe compared with mild cGVHD at onset (71% versus 88%,
P ¼ .039), platelet counts < 100 g/L (55% versus 96%, P <
.0001), and Karnofsky performance score < 80% at onset ofTable 6
Signiﬁcant Differences in Cellular and Plasma Biomarkers in Patients Never Experien
Progressive Onset cGVHD: Results of Univariate Analysis*
Variable Never
cGVHD
De Novo
cGVHD
Quie
cGV
CD19þ B cells  106/L 261 213 151
CD19þCD21low B cells, % 9.9 15.4 18
CD19þIgDCD27þ memory B cells, % 4.4 5.6 5
BAFF, ng/mL 3.2 5.4 5
CD4þ T cells  106/L 241 429 422
CD4þCD45RAþ T cells, % 14.5 28.6 29
CD4þCD45RAþCD31þ T cells, % 6.8 13.8 15
CD3CD56þ NK cells  106/L 233 208 188
CD14þCD16þ monocytes  106/L 11.3 33.1 24
Signiﬁcant parameters are marked in bold.
* In patients with cGVHD, peripheral blood samples were obtained at ﬁrst diagn
were compared to samples obtained from patients never experiencing cGVHD at tcGVHD (59% versus 86%, P ¼ .002) were signiﬁcantly
associatedwith worse OS. Only the composite variable CD3þ/
CD4þ T cells at diagnosis of cGVHD had a signiﬁcant impact
on OS (P ¼ .01; HR, .63; 95% CI, .44 to .90).
DISCUSSION
Chronic GVHD has remained a serious complication of
HCT and is the leading cause of mortality ranging, with rates
between 30% and 50% in long-term survivors [1-3]. It is a
pleomorphic syndrome with autoimmune features and can
affect multiple organs with various degrees of severity.
We evaluated cellular and soluble biomarkers previously
shown or hypothesized to be associated with cGVHD from
patients enrolled in a large prospective clinical trial. This
study has numerous strengths. First, consecutive, unselected
patients frequentlymonitored for cGVHD activity at the same
institution were enrolled and expert clinicians diagnosed
cGVHD and its severity according to NIH deﬁnitions [4].
Second, serial analyses were performed starting on day 100
after HCT and included samples from ﬁrst diagnosis of
cGVHD. Previous studies either used the old Seattle criteria
for diagnosis of cGVHD [40] or focused on patients with
long-lasting cGVHD instead of newly diagnosed patients.
Finally, we used time-matched controls, those never expe-
riencing cGVHD and monitored at the same institution, to
allow correction for immune reconstitution of each cellular
subpopulation, an issue frequently not addressed in previous
trials. Therefore, this study provides for the ﬁrst time results
on cellular biomarkers in a large patient cohort with
NIH-deﬁned cGVHD.cing cGVHD and Those Newly Diagnosed with De Novo cGVHD or Quiescent/
scent/Progressive
HD
P Value (Never
versus De Novo)
P Value (Never versus
Quiescent/Progressive)
.143 .006
.2 .044 .002
.6 .659 .609
.9 .012 .003
<.001 .002
.3 <.001 <.001
.5 <.001 <.001
.303 .011
.3 .062 .048
osis of cGVHD before initiating immunosuppressive medication and results
he same predeﬁned time points after HCT.
Table 7
Logistic Regression Analysis of Cellular and Plasma Biomarkers as well as
Clinical Parameters for First Diagnosis of cGVHD
Variable HR 95% CI P Value
CD3CD56þ/CD3CD56high NK cells .44 .21-.91 .029
CD3þ/CD4þ T cells 1.45 .76-2.73 .250
CD4þCD45RAþ/CD4þCD45RAþCD31þ T cells 2.32 1.15-4.68 .018
BAFF/CD19þ/CD19þCD21low B cells 3.38 1.53-7.49 .003
Signiﬁcant parameters are marked in bold.
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cells and CD4þCD45RAþCD31þ T cells as independent diag-
nostic biomarkers of overall new-onset cGVHD including
NIH-deﬁned mild severity. ROC analysis allowed distinction
of patients with clinically signiﬁcant cGVHD and those never
experiencing cGVHD. Our group previously described ab-
normalities of B cell function seen as distortion of B cell
homeostasis with a signiﬁcant increase of CD19þCD21low B
cells in patients with long-lasting cGVHD [8,9]. Here, we
present results in patients with newly diagnosed cGVHD
occurring a median of 5.7 months after HCT and we conﬁrm
the importance of the CD19þCD21low B cell subpopulation in
cGVHD. Of note, Suryani et al. observed that the ﬁrst B cells to
be exported from the BM into the periphery after HCT are
CD21low transitional B cells, which subsequently differentiate
towards CD21high transitional B cells that are the precursors
of the naïve B cell pool in PB and tissues [41].
The reason for accumulation of CD21low B cells in cGVHD
patients remains unclear. One possibility is increased
replenishment from the BM because of enhanced decline of B
cells in the periphery. On the other hand, CD21 expression on
previously CD21þ B cells might become downregulated or
silenced, indicating hyperactivated B cells. This cell type has
been referred to as exhausted B cells because of its hypo-
proliferative behavior [42]. Similar ﬁndings were obtained in
systemic lupus erythematosus (SLE) patients with abnor-
mally low CD21 expression compared with healthy
individuals [43]. In experimental SLE-prone mice, decreasedFigure 3. Receiver operating characteristic (ROC) curves for CD3CD56þ/
CD3CD56high NK cells, CD3þ/CD4þ T cells, CD4þCD45RAþ/
CD4þCD45RAþCD31þ T cells, BAFF/CD19þ/CD19þCD21low B cells. ROC curves
of the composite parameters are shown. indicates the reference line.levels of CD21 expression on B cells were observed before
clinical signs became apparent [44]. The CD21 molecule has
been shown to play a decisive role for the generation of T
celleindependent immune responses in which provision of
the multimerized ligand for CD21, ie, CD3d, was shown to
lower the actual amount of antigen needed to induce a
robust immunoglobulin response by a factor of up to
10,000-fold [45]. Thus, it is intriguing as towhy, in a situation
when B cell autoreactive processes are highly likely to
contribute to active cGVHD or SLE, CD21 should be down-
regulated. One possible reason would be a self-protective
mechanism limiting the disastrous effects of chronic B cell
activation from within the system. It has been shown that
CD21 expression is mainly regulated by an intronic silencer,
which has lineage and B cell stage-speciﬁc activity [46].
Activation of the repressor might explain why distinct B cells
increasingly lose CD21. It has been reported that CD21
expression is regulated by methylation of CpG islands within
the CD21 promoter and chromatin modiﬁcation through
histone deacetylation [47]. Future studies will have to assess
whether the opposite occurs in CD21low B cells derived from
cGVHD patients.
Chronic GVHD reportedly is associated with increased
CD3þ T cells, Th17 cells, and both CD4þ and CD8þ effector
memory T cells [48]. We observed signiﬁcantly higher per-
centages of CD4þCD45RAþCD31þ T cells at onset of cGVHD, a
ﬁnding that has previously not been reported. Matsuoka
et al. observed increased CD4þCD45RAþCD31þ T cells during
the ﬁrst year after HCT in the overall patient cohort [28].
CD31 reportedly is an excellent ﬂow cytometric marker of
recent thymic emigrants in CD4þCD45RAþ naïve T cells
containing high numbers of TREC-bearing cells after HCT
[19,20].
Several reasons might account for the elevated percent-
ages of CD4þCD45RAþCD31þ T cells observed in patients
with cGVHD. Increased numbers of CD4þCD45RAþCD31þ T
cells might also be generated by post-thymic expansion in
the periphery. That, in principle, human naïve T cells can
proliferate post-thymically while retaining their naïve
phenotype and functional characteristics has been shown
previously. Post-thymic expansion of T cells is used by the
immune system to compensate for reduced thymic output of
CD4þCD45RAþ T cells and can be regularly observed in the
elderly as is reﬂected by reduced TREC levels of
CD4þCD45RAþCD31þ T cells [49]. As TCR engagement
would induce down-modulation of CD31 expression,
cytokine-driven homeostatic proliferation of naïve T cells
might take place, resulting in low-level autoreplication of
CD4þCD45RAþCD31þ T cells. Of note, lymphopenia-induced
homeostatic proliferation reportedly exploits cytokine over-
abundance after lymphopenia to rapidly generate T cells in
the periphery and is characterized by a slow proliferation
rate [21,50]. In Matsuoka et al.’s report, the majority of naïve
conventional T cells expressed CD31, but few had Ki-67,
indicating a low proliferation rate within this population
[28].
Post-thymic proliferation of naïve T cells, including
CD4þCD45RAþCD31þ T cells, and their differentiation into
memory/effector T cells after cognate interaction with
foreign antigens has been suggested by Kohler et al. [20].
Furthermore, CD4þCD45RAþCD31þ T cells display a poly-
clonal TCR repertoire and immunity against neoantigens
depends on CD4þ T cells recognizing a broad repertoire
[20,24]. These ﬁndings could increase the probability of
autoreactive and alloreactive T cell development in patients
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conditioning regimens and/or acute GVHD leads to dysre-
gulation of central tolerance mechanisms during the recon-
stitution of the immune system after HCT [18,51]. Disruption
of thymic apoptosis and failure to eliminate the majority of
self-reactive or potentially autoreactive T lymphocytes might
cause dysregulation of central tolerance mechanisms during
the reconstitution phase after HCT, leading to impairment of
lymphocyte homeostasis and self-tolerance [18]. This might
not only result in an increased pool of CD4þCD45RAþCD31þ T
cells with low-afﬁnity, self-reacting TCR [18], but also to
escape of autoreactive T cells. Their expansion may cause
further activation of effector functions, including cytokine
secretion, cytolytic activity, and antibody production due to B
cell activation and hyper-reactivity, resulting in clinically
noticeable organ damage [52].
In our study, CD19þCD21low B cells and CD4þCD45
RAþCD31þ T cells assessed on day 100 after HCT signiﬁcantly
predicted later development of cGVHD independently of
clinical parameters. So far, few immune cell populations,
including plasmacytoid dendritic cells, natural killer cells,
and Treg cells associated with risk of subsequent cGVHD
have been reported [48]. No main impact of prior acute
GVHD on cellular biomarkers was observed in our cohort
when comparing patients with de novo onset type with
those with quiescent or progressive onset type of cGVHD.
Thus, CD19þCD21low B cells and CD4þCD45RAþCD31þ T cells
can serve as predictive biomarkers in all onset types of
cGVHD and are not inﬂuenced by corticosteroid medication,
which is in contrast to BAFF [39]. Of note, Kitko et al. recently
reported a correlation of plasma chemokine (C-X-C motif)
ligand 9 (CXCL9) concentrations with diagnosis of cGVHD
[53]. However, CXCL9 levels were impacted by immuno-
suppressive therapy and thus, CXCL9 plasma concentrations
in the patient cohort with long-lasting and treated cGVHD
were not signiﬁcantly different compared with control pa-
tients without cGVHD.
An important focus of current GVHD research is to
develop biomarkers that might serve as diagnostic tools and
to inform patient prognosis and treatment strategies. Here,
we present cellular diagnostic biomarkers for new-onset
NIH-deﬁned cGVHD in a large patient cohort that have not
been affected by corticosteroid medication and, thus, can be
investigated in all onset types of cGVHD. Furthermore,
elevation of the same cellular biomarkers on day 100 after
HCT preceded overt clinical manifestations of cGVHD and, if
conﬁrmed in a validation study, could be used to guide
clinical trials testing pre-emptive therapeutic strategies. In
cGVHD, biomarkers correlating with patient outcome
currently are lacking. In our study, the composite variable
CD4þCD45RAþ/CD4þCD45RAþCD31þ T cells assessed on day
100 and at diagnosis of cGVHD had a signiﬁcant impact on
NRM in univariate analysis.
In summary, our ﬁndings provide convincing evidence
that elevated percentages of CD19þCD21low B cells and
CD4þCD45RAþCD31þ T cells can serve as predictive and
diagnostic biomarkers for new onset cGVHD. This study also
provides new insight into the pathogenesis of cGVHD. The
clinical utility of these cellular biomarkers, however, needs to
be further deﬁned in future prospective studies, including
their validation in another independent patient cohort.
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